VKTX Key Statistics, Chart & Performance
The current stock price of VKTX is 32.22 USD. In the past month the price decreased by -11.51%. In the past year, price decreased by -6.61%.
VKTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VKTX. When comparing the yearly performance of all stocks, VKTX is a bad performer in the overall market: 74.94% of all stocks are doing better.
VKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VKTX. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability.
VKTX Financial Highlights
Over the last trailing twelve months VKTX reported a non-GAAP Earnings per Share(EPS) of -2.12. The EPS decreased by -127.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.11% | ||
| ROE | -33.29% | ||
| Debt/Equity | 0 |
VKTX Forecast & Estimates
23 analysts have analysed VKTX and the average price target is 95.94 USD. This implies a price increase of 197.77% is expected in the next year compared to the current price of 32.22.
VKTX Ownership
About VKTX
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Company Info
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA 92130 US
CEO: Brian Lian
Employees: 50
Phone: 18587044660
VIKING THERAPEUTICS INC / VKTX FAQ
What does VIKING THERAPEUTICS INC do?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
What is the stock price of VIKING THERAPEUTICS INC today?
The current stock price of VKTX is 32.22 USD. The price decreased by -5.49% in the last trading session.
Does VKTX stock pay dividends?
VKTX does not pay a dividend.
What is the ChartMill rating of VIKING THERAPEUTICS INC stock?
VKTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about VIKING THERAPEUTICS INC (VKTX) stock?
23 analysts have analysed VKTX and the average price target is 95.94 USD. This implies a price increase of 197.77% is expected in the next year compared to the current price of 32.22.
How is the valuation of VIKING THERAPEUTICS INC (VKTX) based on its PE ratio?
VIKING THERAPEUTICS INC (VKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.12).
What is the employee count for VKTX stock?
VIKING THERAPEUTICS INC (VKTX) currently has 50 employees.